vaccine-approval

FDA advisors voted unanimously to approve Moderna's seasonal mRNA flu vaccine, mRNA-1010, after initial rejection by a Trump appointee. The vaccine showed 27% better efficacy than standard flu shot and stronger immune response than high-dose vaccine in older adults.